JP2019508032A - がん性疾患をステージング、タイピングおよび処置するための手段および方法 - Google Patents

がん性疾患をステージング、タイピングおよび処置するための手段および方法 Download PDF

Info

Publication number
JP2019508032A
JP2019508032A JP2018539138A JP2018539138A JP2019508032A JP 2019508032 A JP2019508032 A JP 2019508032A JP 2018539138 A JP2018539138 A JP 2018539138A JP 2018539138 A JP2018539138 A JP 2018539138A JP 2019508032 A JP2019508032 A JP 2019508032A
Authority
JP
Japan
Prior art keywords
dcc
cells
somatic
cancer
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018539138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508032A5 (enExample
Inventor
クライン，クリストフ
シャイトラー，セバスチャン
ヴェルナークライン，メラニー
ホフマン，マルティン
ホダック，イサベル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Regensburg
Original Assignee
Universitaet Regensburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Regensburg filed Critical Universitaet Regensburg
Publication of JP2019508032A publication Critical patent/JP2019508032A/ja
Publication of JP2019508032A5 publication Critical patent/JP2019508032A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2018539138A 2016-01-27 2017-01-27 がん性疾患をステージング、タイピングおよび処置するための手段および方法 Pending JP2019508032A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16152883.1A EP3199641B1 (en) 2016-01-27 2016-01-27 Means and methods for staging, typing and treating a cancerous disease
EP16152883.1 2016-01-27
PCT/EP2017/051789 WO2017129753A1 (en) 2016-01-27 2017-01-27 Means and methods for staging, typing and treating a cancerous disease

Publications (2)

Publication Number Publication Date
JP2019508032A true JP2019508032A (ja) 2019-03-28
JP2019508032A5 JP2019508032A5 (enExample) 2020-03-05

Family

ID=55310656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018539138A Pending JP2019508032A (ja) 2016-01-27 2017-01-27 がん性疾患をステージング、タイピングおよび処置するための手段および方法

Country Status (10)

Country Link
US (1) US11702701B2 (enExample)
EP (2) EP3199641B1 (enExample)
JP (1) JP2019508032A (enExample)
KR (1) KR20180102674A (enExample)
CN (1) CN108770360B (enExample)
AU (1) AU2017211976B2 (enExample)
CA (1) CA3012404A1 (enExample)
ES (1) ES2905208T3 (enExample)
SG (1) SG11201805990XA (enExample)
WO (1) WO2017129753A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037113A2 (en) * 2000-11-03 2002-05-10 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
US20140227692A1 (en) * 2011-07-08 2014-08-14 Deborah W. Neklason Methods of detecting hereditary cancer predisposition
JP2015500035A (ja) * 2011-12-10 2015-01-05 アボツト・モレキユラー・インコーポレイテツド 悪性黒色腫の診断および悪性黒色腫の転移の予後予測のための物質および方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673541B1 (en) 1998-09-18 2004-01-06 Micromet Ag DNA amplification of a single cell
ITRM20110149A1 (it) * 2011-03-25 2012-09-26 Massimo Zollo Biomarcatore per la rilevazione di cellule tumorali circolanti e relativi metodi e kit di rilevazione.
WO2015023551A1 (en) * 2013-08-13 2015-02-19 Bionumerik Pharmaceuticals, Inc. Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types
US10273538B2 (en) 2014-02-05 2019-04-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Error-free sequencing of DNA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037113A2 (en) * 2000-11-03 2002-05-10 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
US20140227692A1 (en) * 2011-07-08 2014-08-14 Deborah W. Neklason Methods of detecting hereditary cancer predisposition
JP2015500035A (ja) * 2011-12-10 2015-01-05 アボツト・モレキユラー・インコーポレイテツド 悪性黒色腫の診断および悪性黒色腫の転移の予後予測のための物質および方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF DERMATOLOGY (2014) VOL.171, PP.108-114, JPN6020038187, ISSN: 0004362082 *
CURR. ONCOL. REP. (2012) VOL.14, PP.63-69, JPN6020038186, ISSN: 0004576208 *
JOURNAL OF PATHOLOGY (2014) VOL.233, PP.39-50, JPN6020038188, ISSN: 0004362083 *
PLOS MEDICINE (2014) VOL.11, NO.2, E1001604, PP.1-17, JPN6020038189, ISSN: 0004362084 *

Also Published As

Publication number Publication date
AU2017211976B2 (en) 2022-09-22
US11702701B2 (en) 2023-07-18
AU2017211976A1 (en) 2018-08-02
CN108770360A (zh) 2018-11-06
EP3199641B1 (en) 2021-09-29
KR20180102674A (ko) 2018-09-17
CN108770360B (zh) 2022-06-14
WO2017129753A8 (en) 2017-10-19
EP3199641A1 (en) 2017-08-02
WO2017129753A1 (en) 2017-08-03
ES2905208T3 (es) 2022-04-07
SG11201805990XA (en) 2018-08-30
CA3012404A1 (en) 2017-08-03
US20190062845A1 (en) 2019-02-28
EP3408411A1 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
Shao et al. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade
Perrone et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
Oliveira-Costa et al. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells
Lorenzo-Martín et al. VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma
Vincenzo et al. Application of molecular biology of differentiated thyroid cancer for clinical prognostication
US11505831B2 (en) Compositions and methods comprising digital signatures to predict response and resistance to targeted therapy and immunotherapy
US20130224192A1 (en) Method for the prognosis of the progression of cancer
US20220025004A1 (en) Compositions and methods related to site-specific identification of rna modifications
Gasparini et al. Prognostic determinants in epithelioid sarcoma
Miao et al. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis
US20150322533A1 (en) Prognosis of breast cancer patients by monitoring the expression of two genes
Lee et al. Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis
WO2021063970A1 (en) PREDICTIVE BIOMARKERS FOR TREATMENT OF A CANCER PATIENT WITH TGFβ SIGNALING PATHWAY INHIBITORS
JP2019508032A (ja) がん性疾患をステージング、タイピングおよび処置するための手段および方法
Gimeno-Valiente et al. DNA methylation co-operates with genomic alterations during non-small cell lung cancer evolution
US20230332239A1 (en) Methods of treating cancer
WO2021063972A1 (en) Cthrc1 as biomarker for a tgfbeta-activated tumor microenvironment
AU2016269632A1 (en) Method for identifying subjects with aggressive melanoma skin cancer at diagnosis
Jacobi et al. EZH2 alters aggressive variant prostate cancer subtype evolution, but is not required for neuroendocrine prostate cancer
EP4455308A1 (en) Il-7r gene signatures
Berner The Molecular Basis of Exceptional Survivorship in Stage 4 Colorectal Cancer
Manca et al. NGS-Based Analysis of Atypical Deep Penetrating Nevi. Cancers 2021, 13, 3066
JP2018164442A (ja) 皮膚有棘細胞癌の判定、予防又は治療方法
JP2014221065A (ja) ２つの遺伝子の発現の観察による乳癌患者の予後診断
Isidori Addressing tumor heterogeneity in esophageal adenocarcinoma through different molecular approaches

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210409

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210824

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211222

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20220111

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220111

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230221

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230724